Cardiol Therapeutics Inc Sustainability Reports

Cardiol Therapeutics Inc. is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate is CardiolRx, an oral cannabidiol solution in clinical development for treating pericarditis and myocarditis.

Sector: Manufacturing

Country: Canada

Exchange: Toronto Stock Exchange

LEI: 549300EXSOITGMUJOK20

FIGI: BBG00M0GNQ75

7 reports from 2019 to 2025

• Cardiol Therapeutics Inc 2025 Consolidated Financial Statements
• Cardiol Therapeutics Inc 2024 Consolidated Financial Statements
• Cardiol Therapeutics Inc 2023 Consolidated Financial Statements
• Cardiol Therapeutics Inc 2022 Consolidated Financial Statements
• Cardiol Therapeutics Inc 2021 Financial Statements